NCE-1 Intelligence & Market Opportunity

Voydeya

Danicopan

Immunomodulators

Oral Tablets

Voydeya is an oral complement factor D inhibitor added to standard therapy in adults with paroxysmal nocturnal hemoglobinuria. It helps reduce ongoing hemolysis outside blood vessels, improving anemia.

Approval Date

29-Mar-24

NCE-1 Date

29-Mar-28

NCE Date

29-Mar-29

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

127

2027

181

2028

195

2029

291

2030

335

2031

383

2032

430

Molecule profile

Details & specifications

Molecule

Danicopan

Innovator

ALEXION PHARMACEUTICALS INC

Dosage Form

Oral Tablets

Strength

50 mg and 100 mg

Therapeutic Category

Immunomodulators

Usage

To treat extravascular hemolysis with paroxysmal nocturnal hemoglobinuria

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.